护心方对频发室性早搏患者心率变异性的影响

发布时间：2018-05-27 14:32

本文选题：频发室性早搏 + 护心方　；参考：《南京中医药大学》2016年硕士论文

【摘要】：目的：观察护心方对频发室性早搏患者心率变异性的影响,探讨频发室性早搏患者应用护心方的临床治疗效果,评价护心方治疗频发室性早搏的安全性,为护心方临床治疗频发室性早搏提供数据支持。方法：本研究选取2015年6月至2016年6月在我院就诊的100例患者进行研究,随机数字表法将患者分为治疗组和对照组各50例。治疗组采用护心方治疗,对照组采用美托洛尔治疗。观察两组治疗前后连续R-R间期标准差(SDNN)、平均5分钟R-R间期标准差(SDANN)、相邻RR间期差的均方根(rMSSD)、相邻RR间期差值超过50mm的心搏数占总心搏的百分比(PNN50)、QT离散度、治疗效果、平均心率及不良反应。结果：两组患者性别、年龄等基线资料比较无差异(p0.05)；治疗前两组HRV的SDNN、SDANN、RMSSD和PNN50比较无差异(p0.05),治疗后两组HRV的SDNN SDANN、RMSSD和PNN50与同组治疗前相比明显增高(p0.05),治疗组改善程度优于对照组(p0.05)；两组QTd和QTcd治疗前比较无差异(p0.05),两组治疗后的QTd和QTcd与同组治疗前相比均较下降(p0.05),对照组改善程度不及治疗组(p0.05)；对照组临床治疗有效率为70.00%,治疗组临床治疗有效率为88.00%,组间比较有差异(p0.05)；两组患者治疗前后组内、组间平均心率变化比较均无差异(p0.05)；对照组与治疗组患者副反应发生率分别为18.00%和4.00%,组间比较有差异(p0..05)。结论：频发室性早搏患者应用护心方显效,可以有效延长心率变异性、有效降低QT离散度,并且临床疗效确切,对患者心率作用不大,有效降低了频发室性早搏患者药物治疗过程中的不良情况的发生,临床应用及研究价值较高。
[Abstract]:Objective: to observe the effect of Huxin recipe on heart rate variability in patients with frequent ventricular premature beats, to explore the clinical therapeutic effect of Huxin recipe in patients with frequent ventricular premature beats, and to evaluate the safety of Huxin recipe in treating frequent ventricular premature beats. To provide data support for the clinical treatment of frequent ventricular premature beats. Methods: 100 patients in our hospital from June 2015 to June 2016 were selected and randomly divided into treatment group (n = 50) and control group (n = 50). The treatment group was treated with Huxin recipe and the control group with metoprolol. The continuous R-R interval standard deviation before and after treatment was observed in the two groups. The mean 5-minute R-R interval standard deviation was observed. The RMSSDN of the adjacent RR interval difference was measured. The percentage of the beat number of the adjacent RR interval over 50mm in the total cardiac beat was measured. Mean heart rate and adverse reactions. Results: two groups of patients gender, Before treatment, there was no difference between the two groups in HRV and PNN50. After the treatment, the SDNN SDANNN HRV and PNN50 of the two groups were significantly higher than those of the same group (P 0.05), the improvement of the treatment group was better than that of the control group (p0.05), QTd and PNN50 of the two groups were significantly higher than that of the control group (P 0.05), the improvement of the two groups was better than that of the control group (P < 0.05), and that of the two groups was significantly higher than that of the control group (P < 0.05). There was no difference in QTcd before and after treatment. The QTd and QTcd of the two groups were lower than those of the same group before treatment, the improvement degree of the control group was not as good as that of the treatment group, the effective rate of clinical treatment in the control group was 70. 00g and the effective rate of clinical treatment in the treatment group was 88.000.The effective rate of the treatment group was 88. 00%, while the improvement degree of the control group was less than that of the control group (P 0. 05). There was significant difference between the two groups before and after treatment. There was no significant difference in the mean heart rate between the two groups (p 0.05), and the incidence of side effects in the control group and the treatment group was 18.00% and 4.00, respectively, and there was significant difference between the two groups (p 0. 05). Conclusion: the application of Huxinfang in patients with frequent ventricular premature beats can effectively prolong heart rate variability and reduce QT dispersion. It can effectively reduce the incidence of adverse events in the course of drug therapy in patients with frequent ventricular premature beats, and has high clinical application and research value.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】